Paradigm Biopharmaceuticals enters voluntary administration after Phase 3 setback

Paradigm Biopharmaceuticals Limited (ASX: PAR) entered voluntary administration on 29 September 2026, with Hayden White and Christopher Pattinson of FTI Consulting appointed joint and several administrators after the Melbourne-based biotechnology company suffered a setback in a critical Phase 3 clinical trial. The administrators have taken control of Paradigm’s business, operations and assets and are assessing…

No Cookies | Townsville Bulletin

To use this website, cookies must be enabled in your browser. To enable cookies, follow the instructions for your browser below. Facebook App: Open links in External Browser There is a specific issue with the Facebook in-app browser intermittently making requests to websites without cookies that had previously been set. This appears to be a…

IICA Signs MoU with Association of ARCs

IICA Signs MoU with Association of ARCs The collaboration is expected to strengthen the integration of theoretical knowledge with practical industry experience The MoU establishes a collaborative framework built around three key pillars FinTech BizNews Service     Mumbai, 22 October, 2026: The Indian Institute of Corporate Affairs (IICA), an autonomous body under the…